DPO: Elevating and Maintaining Target Hb Levels in Dialysis

H2 tag- SEO Purpose

CKD: Chronic kidney disease; DPO: Darbepoetin alfa; Hb: Hemoglobin; ESA: Erythropoiesis-stimulating agents.

Cresp logo
A phase III, randomized, open-label, parallel-group, 
multicenter, non-inferiority trial was conducted
95 Chinese dialysis patients with CKD-related anemia 
(ESA-naive)

Population

95 Chinese dialysis patients with CKD-related anemia (ESA-naive)

Mean Hb level: 11.3 g/dL (Darbepoetin Alfa) vs.10.7 g/dL 
(Epoetin Alfa)

Results

  • Mean Hb level: 11.3 g/dL (Darbepoetin Alfa) vs.10.7 g/dL (Epoetin Alfa).
  • Non-inferiority proven: Difference in lower limits of 95% CI was 0.1 g/dL (>−1.0 g/dL).
  • Adverse events incidence: 62.5% (Darbepoetin Alfa) vs. 76.9% (Epoetin Alfa)
Conclusion